Commentary Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.7.103
Epigenetic Reprogramming with DNMT Inhibitors: A Multi-Mechanistic Approach to Enhance Immunotherapy in Glioblastoma
Thomas J. Lai1, Robert M. Prins1,2,3,4, Richard G. Everson1,2*
- 1Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
- 2Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA
- 3Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
- 4Parker Institute for Cancer Immunotherapy, San Francisco, California, USA
Corresponding Author
Richard G. Everson, reverson@mednet.ucla.edu
Received Date: November 05, 2024
Accepted Date: December 04, 2024
Lai TJ, Prins RM, Everson RG. Epigenetic Reprogramming with DNMT Inhibitors: A Multi-Mechanistic Approach to Enhance Immunotherapy in Glioblastoma. J Cancer Immunol. 2025;7(1):39-44.
Copyright: © 2025 Lai TJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Decitabine, Epigenetics, Glioblastoma, Immunotherapy
Recommended Articles
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy
The immune system developed certain checks and balance to control or inhibit the reactivity against normal cells of the body. Uncontrolled immune responses to the non-self entities such as bacteria, viruses, parasites, or mutated self-antigens can cause an inflammatory reaction and autoimmune diseases.
Cancer Nanomedicine: Strategies to Enhance Tumor Delivery and Immunotherapy
Cancer nanomedicine was originally developed for more efficient delivery of chemotherapeutic agents into tumor, and has been extensively employed as a therapeutic for cancer treatment owing to its unique features in drug delivery, diagnosis and imaging, as well as the therapeutic nature of some nanomaterials themselves.
Targeting "Do Not Eat Me" Signal CD47 in Cancer Immunotherapy
Cells of the innate and adaptive arm of the immune system including macrophages, natural killer (NK) cells, neutrophils, T cells, and B cells, etc. are crucial for the maintenance of the body’s homeostatic balance and prevention of multiple diseases including cancer.
Anti-PD1 Therapy in Lynch Syndrome-associated Recurrent Glioblastoma
When a patient is diagnosed with a glioblastoma, they are often blindsided with the diagnosis, experiencing symptoms typically developing over only days to weeks and then often undergoing a craniotomy within days of presentation, only to then be given a terminal diagnosis.